Association between CSVD imaging markers and new stroke at 3 months
| Adjusted HR/cOR (95% CI) | P value | |
| PV-WMH | ||
| Fezakas grade <2 | 1 | |
| Fezakas grade 2 | 1.02 (0.60 to 1.73) | 0.95 |
| Fezakas grade 3 | 0.94 (0.46 to 1.91) | 0.86 |
| Deep-WMH | ||
| Fezakas grade <2 | 1 | |
| Fezakas grade 2 | 0.78 (0.46 to 1.30) | 0.34 |
| Fezakas grade 3 | 0.53 (0.20 to 1.43) | 0.21 |
| Lacune | ||
| Absent | 1 | |
| Present | 1.07 (0.67 to 1.72) | 0.77 |
| BG-PVS | ||
| BG-PVS <10 | 1 | |
| BG-PVS 11–20 | 1.15 (0.69 to 1.89) | 0.60 |
| BG-PVS >20 | 0.66 (0.29 to 1.50) | 0.32 |
| Microbleeds | ||
| 0 | ||
| 1–4 | 0.84 (0.41 to 1.72) | 0.64 |
| ≥5 | 0.87 (0.33 to 2.27) | 0.78 |
*This model was adjusted for age, gender, premorbid mRS score, antiplatelet therapy, body mass index, history of ischaemic stroke, TIA, myocardial infarction, congestive heart failure, known atrial fibrillation or flutter, hypertension, diabetes, hypercholesterolaemia, smoking status, time to randomization, qualifying event and NIHSS score on admission.
BG-PVS, basal ganglia perivascular space; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; PV-WMH, periventricular white matter hyperintensity; TIA, transient ischaemic attack.